Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Giant cell arteritis

Giant cell arteritis

Part of Vasculitis

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Giant cell arteritis

10 trials tracked for Giant cell arteritis: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 133 citations.

10Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 5 Phase 1 1 Other / NA 2
  1. Phase 3 An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) Completed · 133 cited
  2. Phase 4 Tocilizumab Plus a Short Prednisone Taper for GCA Completed · 34 cited
  3. Phase 2 Baricitinib in Relapsing Giant Cell Arteritis Completed
  4. Phase 2 KPL-301 for Subjects With Giant Cell Arteritis Completed
  5. Phase 2 Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis Completed
  6. Phase 2 Tocilizumab for Patients With Giant Cell Arteritis Completed
Show 4 more trials
  1. Phase 2 A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis Completed
  2. Phase 1 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA). Completed
  3. N/A Validation of a Diagnostic Algorithm of Giant Cell Arteritis Completed
  4. N/A Assessment of Giant Cell Arteritis Medical Practices in France Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Giant cell arteritis: what the trials found

Tocilizumab has been evaluated in clinical trials for the management of giant cell arteritis (GCA). In a Phase 3 trial, patients receiving Tocilizumab combined with a 26-week prednisone taper demonstrated significantly higher rates of sustained remission at week 52 compared to those receiving a placebo plus a 26-week prednisone taper (56.0% vs. 14.0%, p<0.0001) 2.

Furthermore, Tocilizumab combined with a 26-week prednisone taper showed significantly higher rates of sustained remission at week 52 compared to placebo plus a 52-week prednisone taper (56.0% vs. 17.6%, p<0.0001) 2. Patients receiving Tocilizumab also demonstrated a significantly longer time to first GCA disease flare compared to the placebo groups (165.0 days vs. 295.0 days, p<0.0001) 2.

Safety data for Tocilizumab in this population indicates that the percentage of participants experiencing adverse events was 79.2% in one cohort and 40.9% in another 8.

Recent results — preliminary, needs further review

  • Tocilizumab combined with glucocorticoids showed a significantly higher number of patients achieving complete remission (17 vs. 4, p=0.0301) and being relapse-free (17 vs. 2, p=0.0010), while requiring a lower cumulative dose of glucocorticoids (43 mg/kg vs. 110 mg/kg, p=0.0005) 6.
  • Prednisone was evaluated in a Phase 2 trial where the treatment group showed a significantly higher sustained remission rate at week 26 (83.2% vs. 49.9%, p=0.0038), a longer time to flare by week 26 (25.1 vs. 12.1, p=0.0263), and a longer time to elevated ESR 3.
  • Secukinumab was evaluated in a Phase 2 trial for sustained remission at week 28 (19% vs. 6%) and week 12 (22% vs. 12%) 4.
  • Abatacept was assessed in a Phase 2 trial with results showing varied relapse-free survival across different groups (p=0.049) 7.

For the clinician treating this condition

  • Tocilizumab combined with a 26-week prednisone taper is associated with significantly higher rates of sustained remission and longer time to first disease flare compared to placebo regimens at week 52 2.
  • Evidence suggests that adding Tocilizumab to glucocorticoid therapy may increase the number of patients achieving complete remission while allowing for a lower cumulative dose of glucocorticoids 6.
  • Tocilizumab has been established in clinical trials for GCA, with reported adverse event rates ranging from 40.9% to 79.2% 8.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis finds 7% incidence of suspected carotid atheromas on dental panoramic radiographs
Radiology & Imaging Meta-analysis
Meta-analysis finds 7% incidence of suspected carotid atheromas on dental panoramic radiographs Dental X-rays May Show Calcified Artery Plaque in Some Patients
This systematic review and meta-analysis of 34 cross-sectional studies in dental practice synthesizes evidence on calcified carotid artery a…
About 7% of dental X-rays show signs of artery plaque, meaning routine scans might reveal hidden heart risks that need medical attention.
Apr 15, 2026